ALECTOR INC (ALEC) Fundamental Analysis & Valuation
NASDAQ:ALEC • US0144421072
Current stock price
2.41 USD
-0.02 (-0.82%)
At close:
2.41 USD
0 (0%)
After Hours:
This ALEC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ALEC Profitability Analysis
1.1 Basic Checks
- ALEC had negative earnings in the past year.
- In the past year ALEC has reported a negative cash flow from operations.
- ALEC had negative earnings in each of the past 5 years.
- ALEC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -48.74%, ALEC perfoms like the industry average, outperforming 47.09% of the companies in the same industry.
- ALEC has a worse Return On Equity (-466.34%) than 78.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.74% | ||
| ROE | -466.34% | ||
| ROIC | N/A |
ROA(3y)-31.71%
ROA(5y)-23.3%
ROE(3y)-219.14%
ROE(5y)-146.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ALEC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ALEC Health Analysis
2.1 Basic Checks
- ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ALEC has more shares outstanding
- ALEC has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, ALEC has a worse debt to assets ratio.
2.2 Solvency
- ALEC has an Altman-Z score of -4.91. This is a bad value and indicates that ALEC is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -4.91, ALEC is doing worse than 63.76% of the companies in the same industry.
- ALEC has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.32, ALEC is not doing good in the industry: 69.38% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.91 |
ROIC/WACCN/A
WACC9.47%
2.3 Liquidity
- ALEC has a Current Ratio of 3.83. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.83, ALEC is in line with its industry, outperforming 46.51% of the companies in the same industry.
- A Quick Ratio of 3.83 indicates that ALEC has no problem at all paying its short term obligations.
- ALEC has a Quick ratio (3.83) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 |
3. ALEC Growth Analysis
3.1 Past
- The earnings per share for ALEC have decreased strongly by -13.01% in the last year.
- ALEC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -79.07%.
- The Revenue has been decreasing by -0.05% on average over the past years.
EPS 1Y (TTM)-13.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
Revenue 1Y (TTM)-79.07%
Revenue growth 3Y-45.99%
Revenue growth 5Y-0.05%
Sales Q2Q%-88.5%
3.2 Future
- The Earnings Per Share is expected to grow by 11.09% on average over the next years. This is quite good.
- Based on estimates for the next years, ALEC will show a very strong growth in Revenue. The Revenue will grow by 25.34% on average per year.
EPS Next Y17.29%
EPS Next 2Y19.59%
EPS Next 3Y11.68%
EPS Next 5Y11.09%
Revenue Next Year24.45%
Revenue Next 2Y27.13%
Revenue Next 3Y9.73%
Revenue Next 5Y25.34%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. ALEC Valuation Analysis
4.1 Price/Earnings Ratio
- ALEC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ALEC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.59%
EPS Next 3Y11.68%
5. ALEC Dividend Analysis
5.1 Amount
- No dividends for ALEC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ALEC Fundamentals: All Metrics, Ratios and Statistics
2.41
-0.02 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)04-30 2026-04-30
Inst Owners77.71%
Inst Owner Change0%
Ins Owners6.64%
Ins Owner Change1.29%
Market Cap265.97M
Revenue(TTM)21.05M
Net Income(TTM)-142.93M
Analysts53.85
Price Target2.94 (21.99%)
Short Float %6.6%
Short Ratio7.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.67%
Min EPS beat(2)13.14%
Max EPS beat(2)18.2%
EPS beat(4)4
Avg EPS beat(4)21.13%
Min EPS beat(4)13.14%
Max EPS beat(4)36.06%
EPS beat(8)8
Avg EPS beat(8)31.35%
EPS beat(12)12
Avg EPS beat(12)36.73%
EPS beat(16)13
Avg EPS beat(16)19.9%
Revenue beat(2)2
Avg Revenue beat(2)67.32%
Min Revenue beat(2)5.84%
Max Revenue beat(2)128.8%
Revenue beat(4)3
Avg Revenue beat(4)74.41%
Min Revenue beat(4)-17.7%
Max Revenue beat(4)180.71%
Revenue beat(8)6
Avg Revenue beat(8)65.17%
Revenue beat(12)9
Avg Revenue beat(12)138.95%
Revenue beat(16)10
Avg Revenue beat(16)102.89%
PT rev (1m)37.14%
PT rev (3m)37.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.6%
EPS NY rev (1m)0.38%
EPS NY rev (3m)8.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)106.9%
Revenue NY rev (1m)-13.79%
Revenue NY rev (3m)23.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.68 | ||
| P/tB | 8.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0.19
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.74% | ||
| ROE | -466.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.71%
ROA(5y)-23.3%
ROE(3y)-219.14%
ROE(5y)-146.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 | ||
| Altman-Z | -4.91 |
F-Score1
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)21.84%
Cap/Depr(5y)37.65%
Cap/Sales(3y)1.3%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
EPS Next Y17.29%
EPS Next 2Y19.59%
EPS Next 3Y11.68%
EPS Next 5Y11.09%
Revenue 1Y (TTM)-79.07%
Revenue growth 3Y-45.99%
Revenue growth 5Y-0.05%
Sales Q2Q%-88.5%
Revenue Next Year24.45%
Revenue Next 2Y27.13%
Revenue Next 3Y9.73%
Revenue Next 5Y25.34%
EBIT growth 1Y-9.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.93%
EBIT Next 3Y-6.35%
EBIT Next 5Y19.78%
FCF growth 1Y20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.95%
OCF growth 3YN/A
OCF growth 5YN/A
ALECTOR INC / ALEC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ALECTOR INC (ALEC) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALEC.
What is the valuation status of ALECTOR INC (ALEC) stock?
ChartMill assigns a valuation rating of 0 / 10 to ALECTOR INC (ALEC). This can be considered as Overvalued.
What is the profitability of ALEC stock?
ALECTOR INC (ALEC) has a profitability rating of 0 / 10.
What is the financial health of ALECTOR INC (ALEC) stock?
The financial health rating of ALECTOR INC (ALEC) is 3 / 10.
What is the expected EPS growth for ALECTOR INC (ALEC) stock?
The Earnings per Share (EPS) of ALECTOR INC (ALEC) is expected to grow by 17.29% in the next year.